Review



cdk4 6 inhibitors  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    MedChemExpress cdk4 6 inhibitors
    Cdk4 6 Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 228 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdk4 6 inhibitors/product/MedChemExpress
    Average 97 stars, based on 228 article reviews
    cdk4 6 inhibitors - by Bioz Stars, 2026-02
    97/100 stars

    Images



    Similar Products

    cdk4 6 inhibitors  (MedChemExpress)
    97
    MedChemExpress cdk4 6 inhibitors
    Cdk4 6 Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdk4 6 inhibitors/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    cdk4 6 inhibitors - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    palbociclib (cdk4/6 inhibitor)  (Pfizer Inc)
    90
    Pfizer Inc palbociclib (cdk4/6 inhibitor)
    In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
    Palbociclib (Cdk4/6 Inhibitor), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/palbociclib (cdk4/6 inhibitor)/product/Pfizer Inc
    Average 90 stars, based on 1 article reviews
    palbociclib (cdk4/6 inhibitor) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cdk4/6 inhibitor palbociclib  (Cayman Chemical)
    90
    Cayman Chemical cdk4/6 inhibitor palbociclib
    In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
    Cdk4/6 Inhibitor Palbociclib, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdk4/6 inhibitor palbociclib/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cdk4 6 inhibitor palbociclib  (MedChemExpress)
    97
    MedChemExpress cdk4 6 inhibitor palbociclib
    In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
    Cdk4 6 Inhibitor Palbociclib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdk4 6 inhibitor palbociclib/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    cdk4 6 inhibitor palbociclib - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    cdk4/6 inhibitor palbociclib  (Selleck Chemicals)
    90
    Selleck Chemicals cdk4/6 inhibitor palbociclib
    In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
    Cdk4/6 Inhibitor Palbociclib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdk4/6 inhibitor palbociclib/product/Selleck Chemicals
    Average 90 stars, based on 1 article reviews
    cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cdk4/6 inhibitor palbociclib s4482  (Selleck Chemicals)
    90
    Selleck Chemicals cdk4/6 inhibitor palbociclib s4482
    In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
    Cdk4/6 Inhibitor Palbociclib S4482, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdk4/6 inhibitor palbociclib s4482/product/Selleck Chemicals
    Average 90 stars, based on 1 article reviews
    cdk4/6 inhibitor palbociclib s4482 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to palbociclib assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.

    Journal: bioRxiv

    Article Title: Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models

    doi: 10.1101/2025.07.14.664768

    Figure Lengend Snippet: In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to palbociclib assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.

    Article Snippet: Palbociclib (CDK4/6 inhibitor) and avelumab (human anti-PD-L1 that recognized murine epitope) were provided by Pfizer SLU España (CPT Grant Request ID: 60314347, Project ID: WI235570).

    Techniques: In Vitro, Derivative Assay, Isolation, Flow Cytometry, Expressing, Fluorescence, In Vivo, Control, Comparison